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T-protein is composed of chorismatemutase (AroQT) fused to the N-terminus of prephenate dehydro-
genase (TyrA). Here, we report the replacement of AroQT with the b1-domain of protein G (Gb1). The
TyrA domain shows a strong dehydrogenase activity within the context of this fusion, and our data
indicate that Gb1-TyrA folds into a dimeric conformation. Amino acid substitutions in the Gb1 domain
of Gb1-TyrA identiﬁed residues involved in stabilizing the TyrA dimeric conformation. Gb1 substitu-
tions in the N-terminal b-hairpin eliminated Gb1-TyrA expression, whereas Gb1-TyrA tolerated Gb1
substitutions in the C-terminal b-hairpin and in the a-helix. All of the characterized variants folded
into a dimeric conformation. The importance of the b2-strand in forming a Gb1 homo-dimerization
interface explains the relevance of the ﬁrst-b-hairpin in stabilizing the dimeric TyrA protein.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Escherichia coli (E. coli) prephenate dehydrogenase (TyrA) is a
member of the highly diverse TyrA protein family [1]. E. coli TyrA
forms part of a bi-functional enzyme known as T-protein, which
catalyzes the rearrangement of chorismate to prephenate via the
chorismate mutase (AroQT) domain and the oxidative decarboxyl-
ation of prephenate to 4-hydroxyphenylpyruvate via the TyrA
domain using NAD+ as a cofactor.
TyrA evolutionary studies grouped together the TyrA protein
from E. coli with the lower Gammaproteobacteria (TyrAb subho-
mology; bi-functional TyrAs) [1]. TyrAb members contain particu-
lar insertions and deletions (indels) that disrupt conserved and
functionally important regions present in the TyrAa subhomology
group (mono-functional TyrAs). The indel presence correlates with
TyrAb fusions to chorismate mutase (AroQT; at the N-terminus of
TyrA from Lower Gammaproteobacteria, 4 orders), to a regulatory
domain named ACT (at the C-terminus of TyrA from the upper
Gammaproteobacteria, Xanthomonadaceae family), to a protein
domain called REG (at the C-terminus of TyrA from Euryarchaea)
or has sequence extensions of unknown function. It has been
suggested that the different TyrA fusions (at the N- or C-terminus
of TyrA) might have evolved to replace those lost TyrA contacts [1].chemical Societies. Published by E
2001, Col. Chamilpa 62210,
.Experimental and theoretical studies have suggested that
the E. coli TyrA domain is intrinsically unstable [1,2], and the
construction of separately expressed AroQT and TyrA domains has
demonstrated that the isolated TyrA domain shows lower expres-
sion and stability than the complete T-protein or the AroQT domain
[2]. Although a crystallographic structure of a complete bi-
functional AroQT/TyrA protein is still lacking [3], it is clear from
published work that a close relationship exists between the AroQT
and TyrA domains. Christopherson (1985) reported that, at low con-
centrations, chorismate activates the activity of E. coli TyrA [4], and
Christendat and Turnbull (1999) described E. coli TyrA mutations
that affected the catalytic properties of both the AroQT and TyrA do-
mains [5]. However, published work also suggests that the contact
interface between the AroQT and TyrA domains could be predomi-
nantly non-speciﬁc. A successful production of a wild-type T-pro-
tein modiﬁed with a C-terminal His-tag was recently reported [2].
According to the Haemophilus inﬂuenza TyrA structure [3] the His-
tag should perturb the potential contact interface between AroQT
and TyrA, causing functional problems to the modiﬁed T-protein.
Despite showing a lower stability, however, the modiﬁed T-protein
retained similar catalytic properties as thewild-type T-protein lack-
ing the His-tag [2].
The fact that the TyrA domain from Haemophilus inﬂuenza has
been expressed and puriﬁed without the AroQT domain suggests
that although the low stability of TyrA may be a contributing
factor, it is not the driving force that maintains these domains aslsevier B.V. All rights reserved.
Fig. 1. A cartoon of the Gb1 structure is shown in the upper portion of the ﬁgure. The single amino acid substitutions made at the ﬁrst or second b-hairpins or at the a-helix
are colored in black. The amino acid sequence of the wild-type, dimeric and MonB Gb1 variants are shown in the lower portion of the ﬁgure. The Gb1 secondary structure
elements are shown to facilitate the structural identiﬁcation of the different residue substitutions. Above the Gb1 wild-type amino acid sequence, the residues belonging to
the protein core are indicated with asterisks.
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the TyrA domain is not stable enough to be expressed and puriﬁed
separate from AroQT; we hypothesize that this lower stability is
attributable to a decreased TyrA dimerization ability rather than
to the loss of some speciﬁc interaction with AroQT.
To demonstrate that the putative AroQT/TyrA contact interface
is not playing a role in T-protein function and to explore whether
alternative protein domains could successfully stabilize the TyrA
domain, we constructed a number of chimeric genes coding for dif-
ferent proteins fused to the N-terminus of TyrA. We found that the
replacement of AroQT by the immunoglobulin-binding b1 domain
of G protein successfully produced a dimeric, functional E. coli TyrA
protein (Gb1wt-TyrA fusion protein). Gb1 is a 56-amino acid
protein that folds into a four-stranded b-sheet packed against an
a-helix (Fig. 1) [6].
The results indicate that, whereas amino acid modiﬁcations in
the second strand of the N-terminal b-hairpin eliminated the
expression of the Gb1wt-TyrA fusion and the TyrA activity, substi-
tutions at the C-terminal b-hairpin (at the b-turn or at protein core
residues) that are known to cause a strong protein-destabilizing
effect in the isolated Gb1 domain were only mildly detrimental
to the expression of the Gb1wt-TyrA fusion and the TyrA activity.
The data support the proposal that the Gb1wt-TyrA protein adopts
a dimeric conformation.
2. Materials and methods
All of the nucleic acid manipulations were performed according
to standard procedures [7]. Restriction enzymes and T4 DNA ligase
were obtained from New England Biolabs (Ipswich, MA, USA).
Roche products were used to amplify the DNA, purify plasmids,
purify DNA fragments, and purify PCR products (Roche Applied Sci-
ence, Indianapolis, IN, USA).2.1. Bacterial strains and plasmids
E. coli MC1061 was used as the host for all of the cloning and
library constructions. FA114 (the FA113 strain [8] deleted for the
DNA segment coding for the T-protein/P-protein region) was used
to overproduce the different protein fusion constructs and to
prepare the bacterial extracts used for the TyrA enzymatic assays.
The pTrc99A plasmid was used as the expression vector.
2.2. Construction of TyrA fusion proteins
To fuse the Gb1 domain or its variants to the N-terminus of
TyrA, we ﬁrst modiﬁed the wild-type gene coding for the bifunc-
tional AroQT-TyrA protein with the substitution, C95Q, placed near
the junction between the domains. This change introduced a PstI
restriction site at the region coding for the AroQT-TyrA protein
junction. The DNA sequence coding for AroQT was ﬂanked with
NcoI and PstI restriction sites. This T-protein construct is referred
to as the ‘pseudo-wild-type T-protein’ in the present work. We
added an NcoI site to the start and a PstI site at the end of the gene
coding for the Gb1 domain or its variants. The Gb1 gene variants
were constructed by inverse-PCR mutagenesis. To fuse the Gb1 do-
main to the C-terminus of TyrA, we ﬁrst introduced an NcoI restric-
tion site at the start of the gene coding for the TyrA protein, and
amino acids Leu94 and Gln95 were changed to Met and Ala,
respectively. Next, a PstI restriction site was added to the end of
the coding region for the TyrA protein. This modiﬁcation added
one Leu and one Gln to the end of the TyrA protein. The gb1 gene
fragment coding for the Gb1 domain to be fused to the C-terminus
of TyrA was cloned between the PstI (at the end of the TyrA gene)
and HindIII (present in the ptrc99A multi-cloning site) restriction
sites. To purify the Gb1-TyrA fusions and the TyrA wild-type pro-
tein, a poly-histidine tail was added to the N-terminus.
Fig. 2. (a) Scheme of the different gene constructions used in this work. (b) The
TyrA activity of the indicated variants. The T-protein activity at 100% was deﬁned as
0.21 nmol of NADH produced per second per milligram of protein extract. (c)
Coomassie-stained SDS–PAGE gel of the total soluble proteins extracted from the
same variants used for the activity assays in (b). Arrows indicate the expected
protein bands for the T-protein (lane 1) and the Gb1-TyrA fusion protein (lane 3).
MW, molecular weight markers.
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For the preparation of crude cell extracts, FA114 cells, harboring
tyrAWT or tyrA variants, were grown at 30 C with agitation
(300 rpm) in 15 ml of LB medium supplemented with antibiotics
until reaching an OD600nm of 0.6. IPTG was then added (0.1 mM
ﬁnal concentration), and the cultures were incubated at 30 C for
another 12 h. The cells were harvested, and approximately 30
OD600nm of cell paste was resuspended in 300 ml of lysis buffer
(0.1 M Tris, 1 mM sodium EDTA, 1 mM dithiothreitol and 50 mM
KCl, pH 7.5; no protease-inhibitor cocktail or PMSF was included
in the buffer). The cells were disrupted by two rounds of 25-second
sonication pulses using a Branson Soniﬁer (Danbury, CT, USA). The
cellular debris was removed by centrifugation for 10 min at room
temperature, and the supernatant (bacterial extract) was collected.
2.4. TyrA activity assays
The TyrA activity wasmeasured as described [9]. The TyrA activ-
ity was determined by monitoring the formation of NADH at
340 nm in 96-well plates using a Saﬁre plate reader controlled by
a Tecan platform (Tecan Group LTD. Männedorf, Switzerland). The
reaction mixtures (150 ll) contained 1–5 ll of bacterial extract or
0.2 lg of puriﬁed protein in 50 mM Tris, 0.5 mM sodium EDTA,
0.1 mg/ml bovine serum albumin (BSA), and 2 mM NAD+. The reac-
tion was initiated by the addition of prephenate (PPA) (0.2 mM ﬁ-
nal concentration). The protein concentrations were measured
using the Bradford method [10] with the BIO-RAD (Life Science Re-
search, Hercules, CA USA) protein assay and BSA as the standard.
2.5. Protein puriﬁcation and size-exclusion chromatography
Cell pellets were resuspended in 5 ml of 50 mM sodium
phosphate buffer (pH 7), 500 mM NaCl, 5% glycerol, and 5 mM
imidazole, lysed by sonication (Branson Soniﬁer 450; 20 s, six times
in 30-s intervals, 50% pulse, 4 C) and centrifuged for 20 min at
12000 rpm at 25 C. The variant polypeptides were puriﬁed from
the soluble cell fraction by loading the cell extract onto a 1-ml nickel
Sepharose column previously equilibrated with the same sonication
buffer. The column was washed with 10ml of 50 mMNaPO4 (pH 7),
500 mMNaCl and 35 mM imidazole. The bound His6-tagged protein
was eluted with 300 mM imidazole in NaPO4 (pH 7) and 500 mM
NaCl. The protein concentrations were measured using the Bradford
method [10]with the BIO-RADprotein assay andBSAas the standard.
To determine the oligomerization state of the protein sample, the
puriﬁed proteins were analyzed by size-exclusion chromatography
using an ÄKTA FPLC system equippedwith a UV detector and a size-
exclusion Superose HR12 column from Amersham Biosciences
(Uppsala, Sweden). The samples were eluted with 20 mM NaPO4
(pH 7) and 20 mM NaCl at a ﬂow rate of 0.5 ml/min. The apparent
molecular masses of the proteins were determined by comparing
the protein elution volumeswith those obtainedusing pure samples
of green ﬂuorescent protein and bovine serum albumin as the MW
standards. The proteins were injected at a 100 lM concentration.
2.6. Protein gel electrophoresis
Total protein (800 lg) of the above-prepared bacterial extracts
was mixed with 20 ll of 5X loading buffer (1X: 62.5 mM Tris [pH
6.8], 2.5% SDS, 10% glycerol, 10% b-mercaptoethanol, and 0.05%
Bromophenol blue) to verify the expression levels of the wild-type
TyrA and TyrA fusions. Samples of 40 lg of total protein were sepa-
rated by 10% SDS–PAGE and stained with Coomassie Blue. The rele-
vant protein bands were identiﬁed by their gel migration compared
with molecular weight markers.3. Results and discussion
3.1. The Gb1 domain can replace the AroQT domain in the T-protein
We succeeded in stabilizing the TyrA domain by fusing the Gb1
domain at the N-terminus of TyrA (Fig. 2). The dehydrogenase
activity of the Gb1wt-TyrA fusion was similar to the level exhibited
by the T-protein. However, the robust TyrA expression, resulting
from the fusion of Gb1 to the N-terminus of TyrA, was completely
lost when Gb1 was fused to the C-terminus of TyrA. The strong
TyrA activity and expression level shown by the Gb1wt-TyrA
fusion eliminated the possibility of any speciﬁc contact interface
between AroQT and TyrA that could be necessary for the T-protein
function. The fact that two completely different protein folds
(AroQT and Gb1) succeeded in stabilizing the TyrA dimeric domain
prompted us to investigate whether the Gb1 domain could possess
dimerization properties that were responsible for mimicking the
structural role played by the natural AroQT partner domain in the
T-protein.
3.2. Altered mutational tolerance of wild-type Gb1 in the context of the
TyrA fusion
Baker and co-workers have identiﬁed the amino acid residues
that stabilize theGb1 folding transition state [11], and those authors
have found that the C-terminal b-hairpin appears to be more
ordered than the N-terminal b-hairpin and a-helix in the folding
transition state (Fig. 1).
We introduced several substitutions into Gb1 to test whether
the effects observed in the Gb1 free protein are also important in
the context of the Gb1-TyrA fusion. Surprisingly, the N-terminal
Fig. 3. (a) Activity of the Gb1MUT-TyrA fusion variants. The TyrA activity at 100% within the context of the Gb1-TyrA fusion was deﬁned as 0.19 nmol of NADH produced per
second per milligram of protein extract. The substituted amino acid position in the Gb1 structure is indicated below the bars. (b) Coomassie-stained SDS–PAGE gel of the total
soluble proteins extracted from the same variants used for the activity assays in (a). The molecular weight markers are indicated with ‘MW’. The arrows indicate the expected
gel migration of the different Gb1-TyrA fusion proteins.
Fig. 4. (a) Gb1 dimeric-TyrA constructions. The TyrA activity at 100% was deﬁned as
0.21 nmol of NADH produced per second per milligram of protein extract. (b)
Coomassie-stained SDS–PAGE gel of the total soluble proteins extracted from the
same variants used for the activity assays in (a). The arrows indicate the expected
protein bands for the T-protein (lane 1) and the Gb1-TyrA fusion protein (lane 2).
Lane 9 corresponds to the molecular weight markers.
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in a slight Gb1 destabilization and had essentially no effect on
the Gb1 folding rate, abolished the expression of the Gb1mut-TyrA
fusion protein. In contrast, all of the tested C-terminal b-hairpin
substitutions (Y45L, D46A, T49A, k50N, F52L and V54A), which
are known to have strong destabilizing effects and/or to slow the
Gb1 folding rate, allowed a substantial amount of Gb1mut-TyrA
expression. The N37A substitution, far removed from the N-termi-
nal and C-terminal b-hairpins, produced a mild alteration in the
Gb1mut-TyrA expression level.
As shown in Fig. 3, none of the Gb1 C-terminal b-hairpin variants
or the a-helix variant reached the expression and activity levels of
Gb1wt-TyrA; this is not surprising because most of the C-terminal
b-hairpin alterations tested are strongly destabilizing. Substitutions
at position N37 could have also perturbed the b-2 strand of the ﬁrst
b-hairpin, thus altering the expression of Gb1mut-TyrA, as residue
N37 contacts residues L12 (located at the b-2 strand of the ﬁrst
b-hairpin) and Y33, which is positioned between T16 (also located
at the b-2 strand of the ﬁrst b-hairpin) and N37.
3.3. AroQT can be replaced with Gb1 dimeric variants to produce a
functional TyrA
Gb1 is well known for its plasticity and ability to fold into differ-
ent oligomeric states in response to mutations. In the work
presented here, TyrA was fused to a number of Gb1 dimeric mole-
cules that have been previously described in the literature (Fig. 1).
These variants included some that are capable of forming head-
to-head (named ‘FtoF’ in this work) or swapped dimers (named
‘Dim’ in this work) and tetramers (named ‘Tetra’ in this work), as re-
ported by Gronenborn and co-workers [12], a head-to-head dimer
that has been reported by Schmid and co-workers (named ‘Hyper’
in this work) [13], and the 1EM7 variant that has been described
by Mayo and co-workers [14]. According to Thoms and coworkers
[13], 1EM7 is able to form head-to-head dimers in the crystalenvironment; Mayo and co-workers have also designed the D1.5
variant that has been shown to form weak dimers in NMR experi-
ments [15].
As shown in Fig. 4, fusions of TyrA with the dimeric Gb1
variants restored TyrA expression. The measured dehydrogenase
Fig. 5. (a) The activity of TyrA fused to a highly stabilized monomeric Gb1 variant
(NuG2 variant) or fused to a dimeric version of NuG2. (b) Coomassie-stained SDS–
PAGE gel of the total soluble proteins extracted from the same variants used for the
activity assays in (a). The arrow indicates the gel migration of the NuG2NuG2D46A-
TyrA fusion protein band. Lane 1 corresponds to the molecular weight markers. The
T-protein and Gb1wt-TyrA constructs are also shown.
Fig. 6. (a) Analytical gel-ﬁltration chromatograms of the indicated Gb1-TyrA
variants and for T-protein using a Superose HR12 column. A total of 40–50 lg of
pure protein was injected onto the column. Pure bovine serum albumin (66 kDa)
and green ﬂuorescent protein (30 kDa) were used as the MW standards. To indicate
the expected monomer peak position graphically, we separated a mixture of the
Gb1T49A-TyrA variant with pure GFP. (b) Comparison of the TyrA activity of the
indicated puriﬁed fusion proteins and puriﬁed T-protein. The TyrA activity at 100%
was deﬁned as 1.74 lmol of NADH produced per second per milligram of pure
Gb1wt-TyrA fusion protein.
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the Gb1wt-TyrA fusion. Importantly, the reported tetrameric Gb1
molecule was unable to restore the TyrA activity and expression
levels.
Gb1 variants with an impressive improvement in folding speed
and stability compared with the wild-type protein have been de-
scribed [16]: the b-turn and part of the ﬁrst and second b-strands
of the ﬁrst b-hairpin were replaced with new sequences predicted
to adopt a type I’ turn or a type II’ turn. The variant containing the
type II’ turn (NuG2) was shown to form dimers when modiﬁed
with extra alterations [17] (a histidine tail at the N-terminus and
a D46A substitution). Interestingly, the Gb1NuG2-TyrA fusion pro-
tein failed to show expression. However, a low but reproducible
TyrA activity and good expression levels were obtained when TyrA
was fused to the NuG2 dimeric version (Gb1NuG2D46A-TyrA var-
iant) (Fig. 5).
3.4. The Gb1MonB-TyrA variant
The MonB Gb1 variant was described by Huang et al. [18].
Gb1MonB is an unstableGb1 variant containingﬁve amino acid sub-
stitutions in the a-helix, 1 substitution in the protein region con-
necting the a-helix to the C-terminal b-hairpin and two
substitutions in the C-terminal b-hairpin (including the highly
destabilizing Y45A substitution). The puriﬁed Gb1MonB-TyrA
fusion protein showed TyrA activity levels that were similar to the
Gb1wt-TyrA fusion protein (Fig. 6b), highlighting the tolerance of
the Gb1wt-TyrA fusion protein to substitutions far from the Gb1b2-strand, including a tolerance to alterations that are strongly
detrimental to Gb1 (Y45A or substitutions at protein core residues).
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Because none of the single-substituted Gb1 variants or the
Gb1 dimeric variants (excepting Gb11EM7-TyrA) fused to TyrA
reached the expression levels of the Gb1wt-TyrA fusion protein,
we measured the speciﬁc activity and oligomerization state
of the puriﬁed Gb1V54A-TyrA, Gb1T49A-TyrA, Gb1F52L-TyrA,
Gb1Hyper-TyrA, Gb1FtoF-TyrA, Gb11EM7-TyrA, Gb1NuG2D46A-
TyrA, Gb1MonB-TyrA, Gb1wt-TyrA, and T-protein constructions.
Our size-exclusion chromatography analysis showed that all of
the characterized fusion proteins adopted a dimeric conformation
(Fig. 6a); we did not ﬁnd a protein peak corresponding to mono-
meric fusion proteins. A considerable broader and displaced peak,
eluting with an apparently higher molecular weight than the ex-
pected dimeric fusion protein, was detected for the Gb1Hyper-TyrA
variant (Fig. 6a). Most of the puriﬁed fusion-protein variants pre-
sented prephenate dehydrogenase activity levels similar to the
activities measured for the Gb1wt-TyrA fusion protein, and
Gb1FtoF-TyrA and Gb1NuG2D46A-TyrA retain TyrA activity levels
similar to those measured for the T-protein (Fig. 6b). We noticed
a signiﬁcant improvement in the prephenate dehydrogenase activ-
ity of the Gb1wt-TyrA fusion protein, compared with the T-protein
(Fig. 6b). A facilitated access to the TyrA active site within the new
partner context (Gb1 is half the size of AroQT) might explain the
observed results.
It is known that wild-type Gb1 forms head-to-head (b-2 to b-20
strand contact interface) or head-to-tail (b-2 to b-30 strand contact
interface) dimers at high protein concentrations [13]. Recently, it
has been proposed that Gb1 is also able to form very weak head-
to-head dimers in dilute solutions [19]. The robust expression
and strong dehydrogenase activity of the Gb1wt-TyrA fusion pro-
tein could be the result of TyrA stabilization by the dimeric confor-
mation of the wild-type Gb1 adopted in the TyrA environment. We
speculate that the weak monomer-monomer interaction of both
TyrA and Gb1 is enforced by the presence of each partner domain.
The increase in the surface area contacts for dimerization contrib-
utes synergistically to shift the equilibrium toward the formation
of the dimer, thus stabilizing both proteins on one side and form-
ing the active site of TyrA (for which residues from both subunits
are required [3]).
4. Conclusions
In this work, we demonstrate that Gb1 can successfully replace
the AroQT domain of the T-protein. The experimental data indicate
that Gb1 adopts a dimeric conformation within the context of the
TyrA fusion. Alterations to the ﬁrst b-hairpin of Gb1 eliminated the
expression of the Gb1-TyrA fusion and the TyrA activity. However,
robust TyrA activity of the Gb1-TyrA fusion protein was observed
despite the amino acid substitutions in the second b-hairpin of
Gb1. We also found that only dimeric Gb1 variants were able to
stabilize the dimeric TyrA protein. The known crucial role of the
b2-strand in forming the Gb1 homo-dimerization contact interface
explains the observed importance of the ﬁrst b-hairpin of Gb1 in
stabilizing the dimeric TyrA protein.Acknowledgements
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